Oncobiologics (NASDAQ:OTLK) vs. Xenetic Biosciences (NASDAQ:XBIO) Financial Contrast

Xenetic Biosciences (NASDAQ:XBIO) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Institutional and Insider Ownership

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 1.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Xenetic Biosciences and Oncobiologics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1	0	0	0	1.00
Oncobiologics	1	2	2	0	2.20

Oncobiologics has a consensus price target of $5.20, suggesting a potential upside of 833.57%. Given Oncobiologics’ stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than Xenetic Biosciences.

Earnings & Valuation

This table compares Xenetic Biosciences and Oncobiologics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98 million	1.67	-$2.68 million	($1.16)	-1.88
Oncobiologics	$1.35 million	100.45	-$62.42 million	($0.77)	-0.72

Xenetic Biosciences has higher revenue and earnings than Oncobiologics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Xenetic Biosciences has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Profitability

This table compares Xenetic Biosciences and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
Oncobiologics	N/A	N/A	-254.82%

Summary

Oncobiologics beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.